Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

  • NCT05826756
  • Not Specified
  • OBSERVATIONAL

Last updated: 2023-04-28

Purpose of  Trial

PEER is an international study, that is Institutional Review Board (IRB) approved and General Data Protection Regulation (GDPR) compliant.

The study objective is to collect longitudinal data to facilitate a rigorous understanding of the diagnostic and treatment experiences of people diagnosed with lung cancer and to identify determinants of treatment heterogeneity. Study data will be used to understand the diagnostic and treatment pathways, explore patient-experience data in different domains (financial impact/quality of life/symptoms) and test the hypothesis that different classes of therapies (chemotherapy/ immunotherapy/ targeted therapy/ surgery/ radiation) impact patient experience (eg., physical function).

Study participants will consent and register for the study and complete an initial baseline survey. They will then be followed for 12 months and receive a monthly survey (11 surveys in total) via email. The development of the surveys was guided by input from patients, clinicians, FDA experts, and incorporates questions from existing patient-reported outcomes (PRO) measures.

Summarized study results will also be posted on LUNGevity's website. External researchers will be able to apply to have limited access to de-identified data.


This study is for people with

Lung Cancer Patients

Caregivers


Interventions being studied

There are no interventions in this study. All participants complete online surveys.

Inclusion Criteria:

* Adults with self-reported lung cancer diagnosis or caregiver of someone with a self-reported lung cancer diagnosis (patient has to be alive)

* Ability to read and answer questions in English

* Access and ability to use a computer or other internet-connected device

Exclusion Criteria:

* Younger than 18

* Healthcare providers and healthcare professionals who provide care to lung cancer patients except for those who are themselves a patient or a caregiver to a loved one.

* Not able to provide informed consent

Register to Save
ELIGIBILITY

Gender: ALL

Age: 18+

Healthy Volunteers: No

Location
Bethesda

LUNGevity Foundation


Maryland, 20814, United States
Primary Contact(s)

Boehringer Ingelheim

Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at ClinicalTrials.gov

Back to Results New Search